Lmp Corporate Loan Fund Inc (TLI) 11.08 $TLI 12.3%

New Post Public Reply Private Reply Replies (0) Message Board

Mar 22, 2015 at 2:16 AM

Lmp Corporate Loan Fund Inc (TLI) 11.08 $TLI

12.3% Return Seen to Date on SmarTrend LMP Corporate Loan Fund Call (TLI)
Comtex SmarTrend(R) - Fri Mar 13, 5:17PM CDT
SmarTrend identified a Downtrend for LMP Corporate Loan Fund (NYSE:TLI) on June 11th, 2013 at $12.76. In approximately 21 months, LMP Corporate Loan Fund has returned 12.30% as of today's recent price of $11.19.
TLI: 11.08 (+0.01)

Legg Mason Partners Fund Advisor, LLC Announces Distributions for the Months of March, April and May 2015
Business Wire - Wed Feb 18, 7:00AM CST
Legg Mason Partners Fund Advisor, LLC announced today that certain closed end funds have declared their distributions for the months of March, April and May 2015.
TLI: 11.08 (+0.01), IGI: 20.72 (+0.06), MNP: 15.52 (+0.08), HIO: 5.33 (+0.03), DMO: 24.07 (unch), SBI: 9.96 (+0.03), LM: 58.27 (+1.36), MHF: 7.66 (+0.08), GDF: 9.59 (+0.14), HYI: 16.15 (+0.15), EHI: 11.06 (+0.12), MTT: 23.85 (-0.16), GDO: 18.14 (+0.07), MHY: 5.14 (+0.02), MMU: 14.03 (+0.18), GFY: 16.62 (+0.09), HIX: 8.04 (+0.07)

LMP Corporate Loan Fund Down 13.8% Since SmarTrend Downtrend Call (TLI)
Comtex SmarTrend(R) - Tue Feb 17, 5:06PM CST
SmarTrend identified a Downtrend for LMP Corporate Loan Fund (NYSE:TLI) on June 11th, 2013 at $12.76. In approximately 21 months, LMP Corporate Loan Fund has returned 13.79% as of today's recent price of $11.00.
TLI: 11.08 (+0.01)

Shares of TLI Down 13.7% Since Downtrend Call on Shares
Comtex SmarTrend(R) - Mon Feb 09, 11:16AM CST
SmarTrend identified a Downtrend for LMP Corporate Loan Fund (NYSE:TLI) on June 11th, 2013 at $12.76. In approximately 20 months, LMP Corporate Loan Fund has returned 13.71% as of today's recent price of $11.01.
TLI: 11.08 (+0.01)

LMP Corporate Loan Fund Inc. Portfolio Composition as of December 31, 2014
Business Wire - Fri Jan 30, 9:00AM CST
LMP Corporate Loan Fund Inc. (NYSE:TLI) announces its portfolio composition as of December 31, 2014.
TLI: 11.08 (+0.01)

LMP Corporate Loan Fund Has Returned 13.2% Since SmarTrend Recommendation (TLI)
Comtex SmarTrend(R) - Thu Jan 08, 4:46PM CST
SmarTrend identified a Downtrend for LMP Corporate Loan Fund (NYSE:TLI) on June 11th, 2013 at $12.76. In approximately 19 months, LMP Corporate Loan Fund has returned 13.24% as of today's recent price of $11.07.
TLI: 11.08 (+0.01)

LMP Corporate Loan Fund Shares Down 13.6% Since SmarTrend's Sell Call (TLI)
Comtex SmarTrend(R) - Wed Dec 31, 5:13PM CST
SmarTrend identified a Downtrend for LMP Corporate Loan Fund (NYSE:TLI) on June 11th, 2013 at $12.76. In approximately 19 months, LMP Corporate Loan Fund has returned 13.56% as of today's recent price of $11.03.
TLI: 11.08 (+0.01)

Certain Closed-End Funds Advised by Legg Mason Partners Fund Advisor, LLC Announce Appointment of New Director
Business Wire - Tue Dec 23, 7:00AM CST
ClearBridge American Energy MLP Fund Inc. (NYSE:CBA), ClearBridge Energy MLP Fund Inc. (NYSE:CEM), ClearBridge Energy MLP Opportunity Fund Inc. (NYSE:EMO), ClearBridge Energy MLP Total Return Fund Inc. (NYSE:CTR), Legg Mason BW Global Income Opportunities Fund Inc. (NYSE:BWG), LMP Capital and Income Fund Inc. (NYSE:SCD), LMP Corporate Loan Fund Inc. (NYSE:TLI), LMP Real Estate Income Fund Inc. (NYSE:RIT), Permal Hedge Strategies Fund I, Permal Hedge Strategies Fund II, Permal Hedge Strategies Portfolio, Western Asset Emerging Markets Debt Fund Inc. (NYSE:ESD), Western Asset Emerging Markets Income Fund Inc. (NYSE:EMD), Western Asset Global Corporate Defined Opportunity Fund Inc. (NYSE:GDO), Western Asset Global High Income Fund Inc. (NYSE:EHI), Western Asset Global Partners Income Fund Inc. (NYSE:GDF), Western Asset High Income Fund II Inc. (NYSE:HIX), Western Asset High Income Opportunity Fund Inc. (NYSE:HIO), Western Asset High Yield Defined Opportunity Fund Inc. (NYSE:HYI), Western Asset Intermediate Muni Fund Inc. (NYSE:SBI), Western Asset Investment Grade Defined Opportunity Trust Inc. (NYSE:IGI), Western Asset Managed High Income Fund Inc. (NYSE:MHY), Western Asset Managed Municipals Fund Inc. (NYSE:MMU), Western Asset Middle Market Debt Fund Inc., Western Asset Middle Market Income Inc., Western Asset Mortgage Defined Opportunity Fund Inc. (NYSE

MO), Western Asset Municipal Defined Opportunity Trust Inc. (NYSE:MTT), Western Asset Municipal High Income Fund Inc. (NYSE:MHF), Western Asset Municipal Partners Fund Inc. (NYSE:MNP), Western Asset Variable Rate Strategic Fund Inc. (NYSE:GFY), and Western Asset Worldwide Income Fund Inc. (NYSE:SBW), (together, the "Funds"

TLI: 11.08 (+0.01), ESD: 15.59 (+0.22), LM: 58.27 (+1.36), SBI: 9.96 (+0.03), EHI: 11.06 (+0.12), GDF: 9.59 (+0.14), GDO: 18.14 (+0.07), MMU: 14.03 (+0.18), GFY: 16.62 (+0.09), RIT: 13.26 (+0.19), EMD: 10.90 (+0.11), IGI: 20.72 (+0.06), MNP: 15.52 (+0.08), EMO: 20.84 (+0.25), SCD: 16.87 (+0.19), HIO: 5.33 (+0.03), CBA: 15.75 (+0.13), DMO: 24.07 (unch), MHF: 7.66 (+0.08), BWG: 15.94 (+0.17), HYI: 16.15 (+0.15), CEM: 24.90 (+0.26), MTT: 23.85 (-0.16), MHY: 5.14 (+0.02), SBW: 11.21 (+0.12), CTR: 19.69 (+0.10), HIX: 8.04 (+0.07)

Downtrend Call Working As LMP Corporate Loan Fund Stock Falls 15.7% (TLI)
Comtex SmarTrend(R) - Wed Dec 17, 9:57AM CST
SmarTrend identified a Downtrend for LMP Corporate Loan Fund (NYSE:TLI) on June 11th, 2013 at $12.76. In approximately 18 months, LMP Corporate Loan Fund has returned 15.67% as of today's recent price of $10.76.
TLI: 11.08 (+0.01)

Legg Mason Partners Fund Advisor, LLC Announces Distributions for the Months of December 2014, January and February 2015
Business Wire - Tue Nov 18, 7:01AM CST
Legg Mason Partners Fund Advisor, LLC announced today that certain closed end funds have declared their distributions for the months of December 2014, January and February 2015.
TLI: 11.08 (+0.01), IGI: 20.72 (+0.06), MNP: 15.52 (+0.08), HIO: 5.33 (+0.03), DMO: 24.07 (unch), LM: 58.27 (+1.36), MHF: 7.66 (+0.08), GDF: 9.59 (+0.14), HYI: 16.15 (+0.15), EHI: 11.06 (+0.12), MTT: 23.85 (-0.16), GDO: 18.14 (+0.07), MHY: 5.14 (+0.02), MMU: 14.03 (+0.18), GFY: 16.62 (+0.09), HIX: 8.04 (+0.07)

LMP Corporate Loan Fund Inc. Portfolio Composition as of September 30, 2014
Business Wire - Thu Oct 30, 8:22AM CDT
LMP Corporate Loan Fund Inc. (NYSE: TLI) announces its portfolio composition as of September 30, 2014.
TLI: 11.08 (+0.01)

9.2% Return Seen to Date on SmarTrend LMP Corporate Loan Fund Call (TLI)
Comtex SmarTrend(R) - Fri Oct 24, 10:04AM CDT
SmarTrend identified a Downtrend for LMP Corporate Loan Fund (NYSE:TLI) on June 11th, 2013 at $12.76. In approximately 17 months, LMP Corporate Loan Fund has returned 9.25% as of today's recent price of $11.58.
TLI: 11.08 (+0.01)

Ex-Dividend Alert: 3 Stocks Going Ex-Dividend Tomorrow: TLI, PMM, HIO
at The Street - Tue Oct 21, 9:02AM CDT
TLI PMM HIO are going ex-dividend tomorrow, Wednesday, October 22, 2014
TLI: 11.08 (+0.01), HIO: 5.33 (+0.03), PMM: 7.27 (unch)

3 Stocks Going Ex-Dividend Tomorrow: TLI, FOF, GAIN
at The Street - Tue Sep 16, 9:06AM CDT
TLI FOF GAIN are going ex-dividend tomorrow, Wednesday, September 17, 2014
TLI: 11.08 (+0.01), FOF: 12.85 (-0.01), GAIN: 7.40 (unch)

3 Stocks Going Ex-Dividend Tomorrow: TLI, PMM, EIM
at The Street - Tue Aug 19, 9:05AM CDT
TLI PMM EIM are going ex-dividend tomorrow, Wednesday, August 20, 2014
TLI: 11.08 (+0.01), EIM: 12.78 (+0.04), PMM: 7.27 (unch)

Legg Mason Partners Fund Advisor, LLC Announces Distributions for the Months of September, October and November 2014
Business Wire - Mon Aug 18, 7:00AM CDT
Legg Mason Partners Fund Advisor, LLC announced today that certain closed end funds have declared their distributions for the months of September, October and November 2014.
TLI: 11.08 (+0.01), IGI: 20.72 (+0.06), MNP: 15.52 (+0.08), HIO: 5.33 (+0.03), DMO: 24.07 (unch), SBI: 9.96 (+0.03), LM: 58.27 (+1.36), MHF: 7.66 (+0.08), GDF: 9.59 (+0.14), HYI: 16.15 (+0.15), EHI: 11.06 (+0.12), MTT: 23.85 (-0.16), GDO: 18.14 (+0.07), MHY: 5.14 (+0.02), MMU: 14.03 (+0.18), GFY: 16.62 (+0.09), HIX: 8.04 (+0.07)

LMP Corporate Loan Fund Inc. Announces Financial Position as of June 30, 2014
Business Wire - Tue Aug 12, 7:00AM CDT
LMP Corporate Loan Fund Inc. (NYSE:TLI) today announced the financial position of the Fund as of June 30, 2014.
TLI: 11.08 (+0.01)

Newer

Older

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Innovent's SINTBILO® Hits Primary Endpoint in Study

Innovent's Latest Breakthrough with SINTBILO® One moment you're sipping coffee, the next you're staring at a clinical milestone. Innovent Biologics has shouted from the rooftops that their drug, SINTBILO® (tafolecimab injection), has wrapped up its Phase 3 CREDIT-5 study, snagging the primary endpoint with both hands. This isn't just any drug; it's marked as the first...

Stavian Group Eyes AI-Driven Southeast Asia Growth

AI and Infrastructure: A New Chapter for Southeast Asia What does Southeast Asia's future look like with AI steering the ship? Well, there's a fresh breeze of change blowing, and right at the heart of it stands Stavian Group. At the recently held inaugural Fortune SEA500 Summit in Ho Chi Minh City, this conglomerate threw its hat into the ring, painting a vision of growth...

Intelligent Communication Forum Eyes Global Ecosystem Shift

China's Grand Vision for Intelligent Communication You know what they say about big ideas—they start in the most bustling of places. And here we are in Wuxi, a city's pulse pounding with ambition, hosting the 2026 China International Intelligent Communication Forum. Picture it: From November 8th to 10th, movers, shakers, and visionaries are scribbling new blueprints for...

Antengene’s AnTenGager-D2 Advances in Cancer Treatment

Antengene's AnTenGager-D2 Offers Fresh Hope Alright, let's dig into the latest buzz from the 2026 Society for Immunotherapy of Cancer conference about Antengene's AnTenGager-D2 platform. If you're not into biotech lingo, buckle up, because this is a ride into the future of cancer treatments—where science fiction might soon become science fact. A Novel Approach to Tumor...

D-Wave's Legal Trouble: Securities Fraud Suit Looms

A Looming Legal Storm for D-Wave Investors Call it another day, another legal tangle in the investing world. This time, it's D-Wave Quantum Inc. (NASDAQ: QBTS) on the receiving end of a securities fraud class action lawsuit. Yeah, those fancy quantum computers they're pushing didn't predict this one coming. The legal arena is getting ready for a bout, and if you've got...

CureGene's Evategrel Aims for Breakthrough in Stroke Care

Revolutionizing Stroke Care: Enter Evategrel When it comes to strokes, time is money—and I'm telling you, this ain't an area where you can afford to twiddle your thumbs. The faster you can get that blood flowing again, the better the chance you've got of walking away with less damage. That's where CureGene's new investigational drug, Evategrel, comes in. Why Evategrel...

Allergan Aesthetics Study Shows Rising Patient Satisfaction

Enhanced Patient Satisfaction with Aesthetic Treatments Dive into the latest studies from Allergan Aesthetics—AbbVie's heavyweight in the beauty battleground. If you've got an ounce of optimism left in this market, their recent findings might just lift your spirits. Phase 4 studies, namely HARMONY IN DIVERSITY and HALO, are showing highly positive results among patients...

Gildan's Crisis: Investors Face Losses Amid Lawsuit

Gildan Investors, Brace Yourself Poor old Gildan Activewear finds itself in hot water again, with a class action lawsuit cropping up like an unexpected storm on farmers' day. Any traders remotely involved with NYSE:GIL should pay damn close attention, because with a December 14, 2026 deadline looming, it's crunch time. The Root of the Lawsuit The plot thickens here,...

JNJ's Dual-Antigen Therapy Shows Promise in Prostate Cancer

Exploring a New Front in Cancer Treatment Johnson & Johnson (NYSE: JNJ) just dropped a bombshell at the Society for Immunotherapy of Cancer (SITC) 2026 Annual Meeting, unveiling data that could reshape prostate cancer care. Their pioneering combo of pasritamig and JNJ-9401, a dual-antigen-targeted therapy, has the scientific community buzzing. Yeah, it's just Phase 1 baby...

GlycoNex Eyes Japanese Market with Denosumab Biosimilar

A Strategic Step into the Japanese Market Alright folks, there's a new kid aiming to shake things up in the biotech neighborhood, and it's GlycoNex with its denosumab biosimilar, SPD8. These guys just tossed their hat in the ring with a regulatory submission to Japan's Pharmaceuticals and Medical Devices Agency (PMDA). If the cosmic forces align, they might snag an...